title: Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.
abstract: Tumor establishment and metastasis are dependent on extracellular matrix proteolysis, tumor cell migration, and angiogenesis. Urokinase plasminogen activator (uPA) and its receptor are essential mediators of these processes. The purpose of this study was to investigate the effect of a recombinant human uPAR antagonist on growth, establishment, and metastasis of tumors derived from human cancer cell lines. A noncatalytic recombinant protein, consisting of amino acids 1-137 of human uPA and the CH2 and CH3 regions of mouse IgG1 (uPA-IgG), was expressed, purified, and shown to bind specifically to human uPAR and to saturate the surface of human tumor cells which express uPAR. Daily i.p. administration of uPA-IgG to nude mice extended latencies of unstaged tumors derived from Lox melanoma and SW48 colon carcinoma cells by 7.7 and 5.5 days, respectively. uPA-IgG treatment did not affect the growth of Lox or KB tumors staged to 200 mg before antagonist treatment commenced. The effect of uPA-IgG on the establishment of micrometastases was assessed in SCID mice. KB head/neck tumor cells were injected in the tail vein and allowed to seed for 48 h before initiation of daily i.p. injections of uPA-IgG for 24 days. The number of lung colonies ranged between 5 and 30% of vehicle-treated mice in two separate experiments. Furthermore, a single 800 microg dose of uPA-IgG administered 1 h prior to tail vein injection of KB cells reduced lung colony formation to just 3.5% of vehicle-treated SCID mice. These data demonstrate that antagonism of uPAR arrested metastasis and inhibited the establishment of primary tumors and micrometastases. Thus, small molecule uPAR antagonists may serve as useful adjuvant agents in combination with existing cancer chemotherapy.
authors.affiliation: Department of Pharmacology, Glaxo Wellcome Research Institute, Research Triangle Park, NC 27709, USA.
authors.forename: D M
authors.initials: DM
authors.lastname: Ignar
authors.forename: J L
authors.initials: JL
authors.lastname: Andrews
authors.forename: S M
authors.initials: SM
authors.lastname: Witherspoon
authors.forename: J D
authors.initials: JD
authors.lastname: Leray
authors.forename: W C
authors.initials: WC
authors.lastname: Clay
authors.forename: K
authors.initials: K
authors.lastname: Kilpatrick
authors.forename: J
authors.initials: J
authors.lastname: Onori
authors.forename: T
authors.initials: T
authors.lastname: Kost
authors.forename: D L
authors.initials: DL
authors.lastname: Emerson
mesh_terms: D000818:Animals; D018450:Disease Progression; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000187:drug effects; D009368:Neoplasm Transplantation; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors* / Q000187:drug effects; D055293:Receptors, Urokinase Plasminogen Activator; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D007074:Immunoglobulin G; D009363:Neoplasm Proteins; C524898:PLAUR protein, human; C524899:Plaur protein, mouse; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D011993:Recombinant Fusion Proteins